Penumbra, Inc. (NYSE:PEN - Free Report) - Stock analysts at William Blair cut their Q3 2025 earnings per share (EPS) estimates for Penumbra in a report released on Tuesday, July 29th. William Blair analyst B. Vazquez now expects that the company will post earnings of $0.90 per share for the quarter, down from their prior forecast of $0.96. William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for Penumbra's current full-year earnings is $3.67 per share. William Blair also issued estimates for Penumbra's Q4 2025 earnings at $1.09 EPS, FY2025 earnings at $3.68 EPS, Q1 2026 earnings at $1.08 EPS, Q2 2026 earnings at $1.22 EPS, Q3 2026 earnings at $1.25 EPS, Q4 2026 earnings at $1.46 EPS and FY2026 earnings at $5.02 EPS.
Several other brokerages also recently weighed in on PEN. Robert W. Baird boosted their price target on Penumbra from $283.00 to $285.00 and gave the company an "outperform" rating in a report on Wednesday, July 30th. Morgan Stanley upped their target price on Penumbra from $260.00 to $266.00 and gave the company an "equal weight" rating in a research note on Thursday. Canaccord Genuity Group raised their price target on Penumbra from $340.00 to $350.00 and gave the stock a "buy" rating in a research note on Wednesday, July 30th. Wells Fargo & Company lowered their price target on Penumbra from $315.00 to $290.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. Finally, Wall Street Zen lowered shares of Penumbra from a "strong-buy" rating to a "hold" rating in a report on Saturday. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $300.47.
Check Out Our Latest Report on Penumbra
Penumbra Trading Down 1.1%
Shares of PEN traded down $2.79 on Thursday, hitting $240.22. 129,867 shares of the stock traded hands, compared to its average volume of 503,765. Penumbra has a 1 year low of $163.63 and a 1 year high of $310.00. The stock's 50 day moving average is $249.42 and its two-hundred day moving average is $267.29. The firm has a market capitalization of $9.37 billion, a P/E ratio of 63.73, a P/E/G ratio of 2.19 and a beta of 0.40. The company has a quick ratio of 4.04, a current ratio of 6.75 and a debt-to-equity ratio of 0.02.
Penumbra (NYSE:PEN - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.05. The company had revenue of $339.46 million for the quarter, compared to analyst estimates of $327.37 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The firm's quarterly revenue was up 13.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.64 EPS.
Insider Buying and Selling at Penumbra
In other Penumbra news, CEO Adam Elsesser sold 16,150 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $233.16, for a total value of $3,765,534.00. Following the transaction, the chief executive officer owned 146,258 shares in the company, valued at $34,101,515.28. The trade was a 9.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $252.70, for a total value of $151,620.00. Following the completion of the transaction, the executive vice president directly owned 66,057 shares of the company's stock, valued at $16,692,603.90. This represents a 0.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 115,735 shares of company stock valued at $30,476,510 over the last 90 days. 5.00% of the stock is owned by corporate insiders.
Institutional Trading of Penumbra
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC lifted its stake in Penumbra by 6.6% during the fourth quarter. Quadrant Capital Group LLC now owns 632 shares of the company's stock worth $150,000 after purchasing an additional 39 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Penumbra by 7.3% during the second quarter. GAMMA Investing LLC now owns 761 shares of the company's stock worth $195,000 after purchasing an additional 52 shares during the period. Baker Avenue Asset Management LP lifted its position in shares of Penumbra by 1.6% in the 4th quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company's stock worth $791,000 after buying an additional 53 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of Penumbra by 16.4% in the 1st quarter. Fifth Third Bancorp now owns 404 shares of the company's stock valued at $108,000 after buying an additional 57 shares during the period. Finally, First Horizon Advisors Inc. grew its position in shares of Penumbra by 404.8% during the 1st quarter. First Horizon Advisors Inc. now owns 106 shares of the company's stock valued at $28,000 after buying an additional 85 shares during the last quarter. Institutional investors own 88.88% of the company's stock.
Penumbra Company Profile
(
Get Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Read More
Before you consider Penumbra, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.
While Penumbra currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
